Latest
Apr
24
China Local Pilots Expedite Access to Innovative Medicine
These local experiments focus on speeding up clinical trials, broadening payment options, and incentivizing hospital listings to accelerate access to innovative drugs and medical devices.
5 min read
Apr
17
Quantifying Innovation: Three Key Signals from NHSA's Draft on New Chemical Drug Launch Pricing
The standout enhancement in the current proposal is the addition of a self-assessment scale. This tool, designed to assign a score that quantifies innovation quality based on the company's self-assessment, plays a crucial role in determining the initial pricing of their drugs.
10 min read
Apr
11
NRDL+ 2024 Annual Executive Debrief: The State of Access for Innovative Medicines in China
In this inaugural annual NRDL+ debrief, we comprehensively examined pivotal developments and trends across basic medical insurance schemes, the commercial
3 min read
Apr
10
Former CFDA Head Bi Jingquan: Challenges and Solutions in China's Innovative Medicine Market
Bi Jingquan, previously at the helm of the China Food and Drug Administration and instrumental in regulatory overhauls that transformed
4 min read
Apr
03
Key Direction for Huiminbao Drug Formulary at China's National Two Sessions
During China's 2024 National Two Sessions in March, Wu Fan, a member of the National Committee of the
3 min read
Mar
27
Pudong Drug Pricing Pilot
#1 Pudong reform pilot permits new drug launch pricing comparable to international markets.
On January 22nd, a joint announcement was
4 min read
Mar
13
China's Basic Medical Insurance Data: Three Key Trends and Ecosystem Implications
The 2022 National Medical Security Industry Development Statistical Bulletin, along with the Basic Medical Insurance operation data for Q1 to
6 min read
Feb
28
Policy Push for Long-Term Huiminbao: The Impact on Innovative Medicine
In early January, the National Administration of Financial Regulation (NAFR) issued a draft titled "Notice on Promoting the Smooth
6 min read
Feb
14
China's DRG/DIP Reform: Bridging Medical Service Pricing and Supporting Tech Innovation
The DRG/DIP payment reform has curtailed the rapid expansion of China's public hospitals, shifting focus to quality
5 min read
Jan
17
Closing the Affordability Gap: Can China’s Commercial Health Insurance Deliver?
At the end of 2021, individual out-of-pocket (OOP) spending in China constituted 27.7% of total healthcare expenditure (THE), soaring
5 min read